Overview
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Eligibility
Inclusion Criteria:
- Biopsy-verified anal cancer
- Eligible for curative intended radiotherapy
- Written and oral consent
Exclusion Criteria:
- Other malignant disease within the past 5 years (excluding basal cell carcinoma)